Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

323 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care.
Sirks MJ, van Dijk EHC, Rosenberg N, Hollak CEM, Aslanis S, Cheung CMG, Chowers I, Eandi CM, Freund KB, Holz FG, Kaiser PK, Lotery AJ, Ohno-Matsui K, Querques G, Subhi Y, Tadayoni R, Wykoff CC, Zur D, Diederen RMH, Boon CJF, Schlingemann RO. Sirks MJ, et al. Among authors: wykoff cc. Acta Ophthalmol. 2022 Nov;100(7):e1522-e1532. doi: 10.1111/aos.15148. Epub 2022 Apr 6. Acta Ophthalmol. 2022. PMID: 35388619 Free PMC article.
Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration: 52-Week Results of Phase 3 Randomized Controlled Study.
Kunimoto D, Yoon YH, Wykoff CC, Chang A, Khurana RN, Maturi RK, Agostini H, Souied E, Chow DR, Lotery AJ, Ohji M, Bandello F, Belfort R Jr, Li XY, Jiao J, Le G, Schmidt W, Hashad Y; CEDAR and SEQUOIA Study Groups. Kunimoto D, et al. Among authors: wykoff cc. Ophthalmology. 2020 Oct;127(10):1331-1344. doi: 10.1016/j.ophtha.2020.03.035. Epub 2020 Apr 9. Ophthalmology. 2020. PMID: 32471729 Free article. Clinical Trial.
Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration.
Khurana RN, Kunimoto D, Yoon YH, Wykoff CC, Chang A, Maturi RK, Agostini H, Souied E, Chow DR, Lotery AJ, Ohji M, Bandello F, Belfort R Jr, Li XY, Jiao J, Le G, Kim K, Schmidt W, Hashad Y; CEDAR and SEQUOIA Study Groups. Khurana RN, et al. Among authors: wykoff cc. Ophthalmology. 2021 Jul;128(7):1027-1038. doi: 10.1016/j.ophtha.2020.11.017. Epub 2020 Nov 19. Ophthalmology. 2021. PMID: 33221326 Free article. Clinical Trial.
Risk of bias: why measure it, and how?
Phillips MR, Kaiser P, Thabane L, Bhandari M, Chaudhary V; Retina Evidence Trials InterNational Alliance (R.E.T.I.N.A.) Study Group. Phillips MR, et al. Eye (Lond). 2022 Feb;36(2):346-348. doi: 10.1038/s41433-021-01759-9. Epub 2021 Sep 30. Eye (Lond). 2022. PMID: 34594009 Free PMC article. No abstract available.
The clinician's guide to p values, confidence intervals, and magnitude of effects.
Phillips MR, Wykoff CC, Thabane L, Bhandari M, Chaudhary V; Retina Evidence Trials InterNational Alliance (R.E.T.I.N.A.) Study Group. Phillips MR, et al. Among authors: wykoff cc. Eye (Lond). 2022 Feb;36(2):341-342. doi: 10.1038/s41433-021-01863-w. Epub 2021 Nov 26. Eye (Lond). 2022. PMID: 34837035 Free PMC article. No abstract available.
323 results